Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N, Terpos E, Galanopoulos A, Kritikou-Griva E, Akel S, Michalis E, Apostolidou E, Georgiadou D, Kouraklis A, Parharidou A, Kokkini G, Symeonidis A, Anagnostopoulos NI, Christakis JI, Tasiopoulou A, Loukopoulos D, Yataganas X. Viniou N, et al. Among authors: symeonidis a. Ann Hematol. 2002 Apr;81(4):182-6. doi: 10.1007/s00277-002-0442-y. Epub 2002 Mar 27. Ann Hematol. 2002. PMID: 11976818 Clinical Trial.
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
Diamantopoulos P, Zervakis K, Zervakis P, Sofotasiou M, Vassilakopoulos T, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Solomou E, Kodandreopoulou E, Papadopoulou V, Korkolopoulou P, Mantzourani M, Kyriakakis G, Viniou NA. Diamantopoulos P, et al. Among authors: symeonidis a. Blood Cancer J. 2017 Feb 17;7(2):e533. doi: 10.1038/bcj.2016.127. Blood Cancer J. 2017. PMID: 28212373 Free PMC article.
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos N, Economopoulos T; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: symeonidis a. Ann Oncol. 2003 Aug;14(8):1299-305. doi: 10.1093/annonc/mdg334. Ann Oncol. 2003. PMID: 12881396 Free article.
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: symeonidis a. Ann Oncol. 2003 Jul;14(7):1039-44. doi: 10.1093/annonc/mdg287. Ann Oncol. 2003. PMID: 12853344 Free article. Clinical Trial.
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: symeonidis a. Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483. Ann Oncol. 2014. PMID: 24356630 Free article.
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panagiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Hoeks M, et al. Among authors: symeonidis a. Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32948844 Free PMC article. No abstract available.
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Kastritis E, et al. Among authors: symeonidis a. Leukemia. 2009 Jun;23(6):1152-7. doi: 10.1038/leu.2008.402. Epub 2009 Feb 19. Leukemia. 2009. PMID: 19225533
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: symeonidis as. Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20. Haematologica. 2015. PMID: 26294729 Free PMC article. No abstract available.
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek Myeloma Study Group. Kastritis E, et al. Among authors: symeonidis a. Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18. Leukemia. 2014. PMID: 24637336
272 results